The short interest data are out for the August 31 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can make or break them. A single failed clinical trial can mean disaster for a stock. 24/7 Wall St. has reviewed the top biotech companies, without focusing on speculative companies.
The August 31 short interest data have been compared with the previous figures, and short interest in these selected stocks increased across the board for this settlement date.
Amgen Inc. (NASDAQ: AMGN) saw its short interest jump to 9.24 million shares from the previous level of 7.53 million. Shares closed Thursday at $153.14, in a 52-week trading range of $127.67 to $181.81.
Biogen Inc. (NASDAQ: BIIB) had its short interest rise to 3.86 million shares from the previous 2.68 million. Shares closed Thursday at $312.62, within a 52-week trading range of $265.00 to $480.18.
Celgene Corp. (NASDAQ: CELG) short interest for this settlement date increased to 12.50 million shares from the previous reading of 10.64 million. Since March, Celgene has recorded a few of its highest readings of the year. The mid-May level was the highest short interest reading year to date. Shares of Celgene closed Thursday at $122.97, in a 52-week range of $83.16 to $140.72.
Gilead Sciences Inc. (NASDAQ: GILD) saw its short interest rise to 25.65 million shares, from 21.73 million in the previous period. The late July reading was the lowest of the year. Shares closed Thursday at $107.25, in a 52-week trading range of $85.95 to $123.37.
ALSO READ: The 6 Most Shorted Nasdaq Stocks
MannKind Corp. (NASDAQ: MNKD) saw its short interest increase to 126.70 million shares. The previous reading was 121.78 million. This is the second highest reading on the year. Shares closed Thursday at $3.75, in a 52-week trading range of $3.25 to $7.88.
Alexion Pharmaceuticals Inc. (NASDAQ: ALXN) short interest increased to 5.39 million, from the previous level of 4.61 million. The mid-June level was far and away the highest reading on the year, and since that time shares have backed off significantly. Shares closed Thursday at $171.65, in a 52-week range of $150.06 to $208.88.
Take Charge of Your Retirement In Just A Few Minutes (Sponsor)
Retirement planning doesn’t have to feel overwhelming. The key is finding expert guidance—and SmartAsset’s made it easier than ever for you to connect with a vetted financial advisor.
Here’s how it works:
- Answer a Few Simple Questions. Tell us a bit about your goals and preferences—it only takes a few minutes!
- Get Matched with Vetted Advisors Our smart tool matches you with up to three pre-screened, vetted advisors who serve your area and are held to a fiduciary standard to act in your best interests. Click here to begin
- Choose Your Fit Review their profiles, schedule an introductory call (or meet in person), and select the advisor who feel is right for you.
Why wait? Start building the retirement you’ve always dreamed of. Click here to get started today!
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
Our expert who first called NVIDIA in 2009 is predicting 2025 will see a historic AI breakthrough.
You can follow him investing $500,000 of his own money on our top AI stocks for free.